EUCTR2004-004871-12-IT进行中（未招募）不适用
An Open-Label Phase 1/2 Study of VELCADE (bortezomib) for Injection in Subjects with Light-Chain (AL)-Amyloidosis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy - Velcade Phase II in AIPCaTreatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.EUCTR2006-001933-16-GRChristos N. Papandreou
进行中（未招募）
1 期
A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Multiple Myeloma who are Candidates for Autologous Transplantation - NDMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaMULTIPLE MYELOMAEUCTR2006-006050-10-ITJANSSEN-CILAG INTERNATIONAL NV98
进行中（未招募）
不适用
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation.EUCTR2006-006050-10-CZJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium97
进行中（未招募）
不适用
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation.Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous TransplantationEUCTR2006-006050-10-PTJanssen-Cilag International, N.V.97
进行中（未招募）
不适用
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation.EUCTR2006-006050-10-HUJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium97